newsfilter
← Latest News
Business Wire·

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,